North America Vaccine Market Size & Outlook, 2026-2033
The vaccine market in North America is expected to reach a projected revenue of US$ 45,670.5 million by 2033. A compound annual growth rate of 5.6% is expected of North America vaccine market from 2026 to 2033.
The North America vaccine market generated a revenue of USD 29,107.1 million in 2025.
The market is expected to grow at a CAGR of 5.6% from 2026 to 2033.
In terms of segment, viral vaccines was the largest revenue generating indication in 2025.
Other Indication is the most lucrative indication segment registering the fastest growth during the forecast period.
Country-wise, Mexico is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
Market revenue in 2025
USD 29,107.1 million
Market revenue in 2033
USD 45,670.5 million
Growth rate
5.6% (CAGR from 2026 to 2033)
Largest segment
Viral vaccines
Fastest growing segment
Other Indication
Historical data covered
2021 - 2024
Base year for estimation
2025
Forecast period covered
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Viral Vaccines, Bacterial Vaccines, Cancer Vaccines, Allergy Vaccines, Other Indication
Key market players worldwide
Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc
Other key industry trends
In terms of revenue, North America region accounted for 40.0% of the global vaccine market in 2025.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 29,451.4 million by 2033.
Rapid advancements in biotechnology and healthcare infrastructure propel vaccine research, development, and distribution are the major factors driving the market growth. Government initiatives promoting immunization and heightened awareness post-pandemic drive vaccine adoption.
For instance, the Hepatitis B Foundation strongly supports the updated adult hepatitis B vaccination recommendations from the U.S. Centers for Disease Control and Prevention (CDC). The Foundation is actively coordinating with a panel of experts to facilitate the effective implementation of these guidelines, aiming to enhance vaccination coverage against this dangerous virus among millions of U.S. adults.
Technological innovations facilitate cold chain logistics, ensuring vaccine efficacy. Moreover, collaborations between pharmaceutical giants and research institutions boost market growth. As the region focuses on preventive healthcare and pandemic preparedness, North America vaccine market is expected to expand, driven by innovation, government support, and growing public health consciousness.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Vaccine Market Outlook will help companies and investors design strategic landscapes.
Viral Vaccines was the largest segment with a revenue share of 64.67% in 2025.
Horizon Databook has segmented the North America vaccine market based on viral vaccines, bacterial vaccines, cancer vaccines, allergy vaccines, other indication covering the revenue growth of each sub-segment from 2021 to 2033.
Rapid advancements in biotechnology and healthcare infrastructure propel vaccine research, development, and distribution are the major factors driving the market growth. Government initiatives promoting immunization and heightened awareness post-pandemic drive vaccine adoption.
For instance, the Hepatitis B Foundation strongly supports the updated adult hepatitis B vaccination recommendations from the U.S. Centers for Disease Control and Prevention (CDC). The Foundation is actively coordinating with a panel of experts to facilitate the effective implementation of these guidelines, aiming to enhance vaccination coverage against this dangerous virus among millions of U.S. adults.
Technological innovations facilitate cold chain logistics, ensuring vaccine efficacy. Moreover, collaborations between pharmaceutical giants and research institutions boost market growth. As the region focuses on preventive healthcare and pandemic preparedness, North America vaccine market is expected to expand, driven by innovation, government support, and growing public health consciousness.
North America Vaccine Market Indication Outlook (Revenue, USD Million , 2021-2033)
Viral Vaccines
Bacterial Vaccines
Cancer Vaccines
Allergy Vaccines
Other Indication
North America Vaccine Market Type Outlook (Revenue, USD Million , 2021-2033)
Subunit Vaccines
Inactivated
Live Attenuated
mRNA Vaccines
Viral Vector Vaccines
North America Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
Oral
Parenteral
Nasal
North America Vaccine Market Age Group Outlook (Revenue, USD Million , 2021-2033)
Pediatric Age Group
Adult Age Group
North America Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital & Retail Pharmacies
Government Suppliers
Others Distribution Channel
Reasons to subscribe to Vaccine Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Vaccine Market Outlook databook
Our clientele includes a mix of Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Vaccine Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Vaccine Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.